



Infectious Diseases

The duration of protection of school-aged BCG vaccination in England: a population-based case–control study

Punam Mangtani,^{1*} Patrick Nguipdop-Djomo,¹ Ruth H Keogh,² Jonathan AC Sterne,³ Ibrahim Abubakar,⁴ Peter G Smith,¹ Paul EM Fine,¹ Emilia Vynnycky,^{5,6} John M Watson,¹ David Elliman,⁷ Marc Lipman,⁸ and Laura C Rodrigues¹

¹Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK, ²Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK, ³School of Social and Community Medicine, University of Bristol, Bristol, BS8 2PS, UK, ⁴Institute for Global Health, University College London, London, WC1N 1EH, UK, ⁵Statistics Modelling and Economics Department, Public Health England, Colindale, London, NW9 5HT, ⁶TB Modelling Group, Centre for Mathematical Modelling In Infectious Diseases and TB Centre, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK, ⁷Whittington Health, St Anns Hospital, Tottenham, N15 3TD, UK and ⁸Royal Free London NHS Foundation Trust, London & UCL Respiratory, Division of Medicine, University College London, London, NW3 2QG, UK

*Corresponding author. Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK. E-mail: Punam.Mangtani@lshtm.ac.uk

Editorial decision 18 June 2017; Accepted 13 July 2017

Abstract

Background: Evidence of protection from childhood *Bacillus Calmette-Guerin* (BCG) against tuberculosis (TB) in adulthood, when most transmission occurs, is important for TB control and resource allocation.

Methods: We conducted a population-based case–control study of protection by BCG given to children aged 12–13 years against tuberculosis occurring 10–29 years later. We recruited UK-born White subjects with tuberculosis and randomly sampled White community controls. Hazard ratios and 95% confidence intervals (CIs) were estimated using case–cohort Cox regression, adjusting for potential confounding factors, including socio-economic status, smoking, drug use, prison and homelessness. Vaccine effectiveness (VE = 1 – hazard ratio) was assessed at successive intervals more than 10 years following vaccination.

Results: We obtained 677 cases and 1170 controls after a 65% response rate in both groups. Confounding by deprivation, education and lifestyle factors was slight 10–20 years after vaccination, and more evident after 20 years. VE 10–15 years after vaccination was 51% (95% CI 21, 69%) and 57% (CI 33, 72%) at 15–20 years. Subsequently, BCG protection appeared to wane; 20–25 years VE = 25% (CI –14%, 51%) and 25–29 years

VE = 1% (CI -84%, 47%). Based on multiple imputation of missing data (in 17% subjects), VE estimated in the same intervals after vaccination were similar [56% (CI 33, 72%), 57% (CI 36, 71%), 25% (-10, 48%), 21% (-39, 55%)].

Conclusions: School-aged BCG vaccination offered moderate protection against tuberculosis for at least 20 years, which is longer than previously thought. This has implications for assessing the cost-effectiveness of BCG vaccination and when evaluating new TB vaccines.

Key words: BCG vaccine, Bacillus Calmette-Guerin, effectiveness, duration, tuberculosis, epidemiology, prevention and control, England

Key Messages

- It is unclear whether protection by school-aged Bacillus Calmette-Guerin (BCG) vaccination against TB continues into adulthood, when most transmission occurs.
- Using a case-control study design based on 677 cases and 1170 controls, we found about 50% protection that lasted 20 years and then waned.
- That BCG attributable protection against tuberculosis lasts longer than previously thought affects its cost-effectiveness and has implications for the evaluation of new TB vaccines.

Background

Tuberculosis (TB) is a major, and potentially preventable, cause of morbidity and mortality globally, with 2 to 3 billion of the world's population infected with *Mycobacterium tuberculosis*,¹ 10% of whom progress to clinical disease.² In 2015, 10.4 million people were estimated to have developed TB.¹ TB incidence increases sharply in young adults³ and most cases of pulmonary disease, the main source of onward transmission, occur in adults. Progress in developing new TB vaccines is slow and Bacillus Calmette-Guerin (BCG) is the only licensed TB vaccine.⁴ The efficacy of BCG in preventing TB varies geographically, particularly for pulmonary TB, with limited evidence of protection in many tropical areas.^{5,6} Recent evidence suggest that BCG may act in part by protecting against infection.⁷ A large UK trial in the 1950s showed good protection against TB for up to 15 years following BCG vaccination of secondary-school children,⁸ confirmed in observational studies to last at least 10 years after introduction into the UK national programme.⁹ Although there are few data on protection, more than 10 years after vaccination,^{10,11} studies in Brazil,¹² in US Native-American populations¹³ and, more recently, in the Norwegian general population¹⁴ suggest BCG protection against TB can last longer. We aimed to provide confirmatory evidence of its durability in a case-control study of school-aged BCG vaccination more than 10 years after vaccination in

England. From the 1950s, BCG (based on the Danish strain)^{15,16} was offered routinely to schoolchildren in the UK aged about 13 years, until the programme was discontinued in 2005.

Methods

From 2102 to 2014, cases and controls were invited to take part in face-to-face interviews and to be examined for a BCG scar. We assessed protection from BCG vaccination administered to children 10–30 years previously, 5-year intervals after vaccination and tested for trends over time by analysing time since vaccination on a continuous scale.

Details of the study design are presented elsewhere.¹⁷ In summary, the study was restricted to persons of White ethnic group born in the UK. Other ethnic groups with a higher risk of TB were offered BCG in infancy. Cases were subjects living in England at diagnosis of a first TB episode notified between 2003 and 2012 to the Enhanced Tuberculosis Surveillance System (ETS) of Public Health England (PHE). Cases not known to be infected with HIV were included if they were between 23 and 38 years old at diagnosis (i.e. born between 1965 and 1989, and aged 13 years between 1978 and 2002). Controls were UK-born subjects of White ethnic group without a previous history of tuberculosis, residing in England, selected from the general population and frequency-matched to cases by birth

cohort (in 5-year bands). For logistic efficiency, recruitment of population-based controls was based on three-stage, self-weighted, cluster sampling across England.¹⁷

Experienced field interviewers carried out Computer-assisted Personal Interviews (CAPIs), following training specific to the study including inspecting both arms of all subjects to identify BCG vaccination scars. The training included scar reading of volunteers with and without scars and examination of photographs. Formal supervisory field visits and blind telephone recall interviews of at least 10% of study participants (selected at random) were conducted for quality control.

No central databases of school vaccination records exist in the UK and records were not kept consistently in local child-health information systems. The classification of BCG vaccination status was based on a combination of participants self-reported history of BCG status (convincing history, probable history, no history) and scar inspection (present, not present, not examined). As BCG was a vaccine given in school at about 12–13 years and usually caused a pustule and then a scar, recall by cases and controls was considered likely to be good. However, several had difficulties recalling whether or not they had had a tuberculin skin test (TST) (children were only eligible for BCG vaccination if they were considered TST-negative). These subjects were not excluded from the analysis. Instead, we reviewed the impact of the likely proportion of unvaccinated participants who would have had a positive TST.

Information on potential confounding factors, including demographic and social variables, was collected and compared in cases and controls. A measure of deprivation at the small area level (average 1500 households) was obtained from Census data based on quintiles of the index of multiple deprivation (IMD) score in 2010.¹⁸ Education was assessed as highest education attainment and household crowding was calculated from current number of people in the household, number of rooms and bedrooms. Ever or never been in prison in the UK or elsewhere was noted, as was a history of being homeless for a week or more, and regular travel (defined as every few years or more often) and long stays (3 months or more) in high-TB-burden regions. Smoking was categorized as never, ex- or current, under or over 20 pack-years. Alcohol consumption was based on frequency as well as quantity of UK standard units and recreational drug use as only non-Class A drugs (e.g. cannabis or solvents) or also using class A drugs (e.g. cocaine and heroin). Information on smoking, alcohol, drug use, prison and homelessness was collected using a Computer-Assisted self-interview (CASI): interviewees entered the data on a laptop and then locked them to be inaccessible to the interviewer before returning the laptop.

Ethics and consent

The study was approved by the UK's NHS National Research Ethics Service Committee. We obtained signed informed consent from those willing to take part. Participants, irrespective of whether they completed the study or not, were given a £15 gift voucher as compensation for their time.

Statistical methods

Cases and controls were compared across quintiles of the IMD score. We cross-tabulated history of BCG receipt and presence and absence of a BCG scar, assessing agreement using Cohen's kappa coefficient.

Hazard ratios (HRs) for the association between BCG vaccination status and TB incidence were estimated using the case-cohort approach, with controls forming the sub-cohort.^{19,20} Controls were considered representative samples from the underlying population, as they were sampled at random from the underlying population within which cases arose (frequency-matched by birth cohort in 5-year bands). TB rates are very low in the underlying population. The above approach allowed efficient use of data on the controls at different ages over time, as well as flexible modelling of VE by time since vaccination.²¹ VE was defined as $VE = 1 - HR$.

Based on a Cox regression model allowing a time-varying association between vaccination status and case-control status, each case was compared at its event time with all controls in the sub-cohort who were still at risk at that time (i.e. were interviewed at an age older than that of the case) and in the same year of birth stratum as the case. The time scale in these analyses was age, and vaccination status was a time-dependent variable. Self-reported age at vaccination, if available, was used to define vaccination status at a given age, otherwise the median age of 12 years in those reporting age at vaccination was assumed. The event time for cases was age at TB diagnosis, and the time of right censoring in controls was the age at interview for the study. Event times among cases were left-truncated on the day before the TB diagnosis date. Model parameters were estimated using a pseudo-partial likelihood analysis with robust standard errors as is required in a case-cohort analysis in which control groups are shared between cases.^{19,20}

HRs were estimated within successive time-since-vaccination intervals, respectively 10–15, 15–20, 20–25 and 25–30 years after vaccination. Log HRs were also modelled as a smooth function of time since vaccination. Flexible models based on restricted cubic splines were compared, using the Akaike information criterion (AIC),²² with a model in which the log HR for BCG vaccination

was assumed to change linearly with time since vaccination.

All Cox models used separate baseline hazards by year of birth, to take into account the frequency-matching of controls by birth cohort. The baseline model was also adjusted for sex. Deprivation level and educational level were considered to be potentially important confounders and were added to the baseline model for separate analyses (partially adjusted model). In addition, other potential confounders were added in a further fully adjusted model, in which potential confounding variables were added one by one, and those judged to be important (i.e. changing the estimated log HR for BCG vaccination by ± 0.25 of the standard error of the log HR) were retained. Variables relating to lifestyle (smoking status, drinking behaviour, drug use) were included as a block in this procedure. Any remaining variables were then added again one by one to the model and assessed for retention as before.

Analyses were conducted first for those who had complete data on the variables included in the final model. In sensitivity analyses, we fitted the baseline and partially adjusted models on all individuals with complete data for the model in question. Analyses were repeated using multiple imputation by chained equations to deal with missing data, under a 'missing at random' (MAR) assumption.²³ (See details in [Supplementary Methods](#), available as [Supplementary Data](#) at *IJE* online.)

Results

Of 1602 potentially eligible cases, 1047 (65%) were contacted successfully. Of these, 60 were ineligible (not born in the UK or not White) and 53 had difficulties precluding participation such as frailty. Of the remaining 934, 257 (28%) refused and 677 (72%) were enrolled.¹⁷ Of those enrolled, 534 (80%) had pulmonary disease, 85% bacteriologically confirmed, the rest had extra-pulmonary disease of which 53% were laboratory confirmed.

We recruited controls by sampling 9424 residential addresses. For 13%, the address no longer existed or no one was at the address after repeated visits on different days and times. Among 8176 screened addresses, 1790 (22%) had at least one eligible resident. We recruited from these addresses 1170 controls—a 65% response rate.¹⁷

The distribution of visits by time of day and by day of week was similar in cases and controls.¹⁷ The proportions of contactable cases was slightly lower for those living in more deprived areas based on IMD quintiles. The proportion of addresses successfully screened to identify eligible controls was similar across IMD quintiles (see [Supplementary Table 1](#), available as [Supplementary Data](#) at *IJE* online). Among eligible cases contacted, the refusal

rate was slightly higher for those living in the least deprived quintiles. The proportion of addresses successfully screened to identify eligible controls was similar across IMD quintiles. Among subjects identified as eligible to be controls, the refusal rate was similar across IMD quintiles, though slightly higher than in cases (see [Supplementary Figure 1](#), available as [Supplementary Data](#) at *IJE* online)

Cases were more likely to be male, more likely to be in the most deprived IMD quintile, more likely to live in overcrowded households and had fewer educational qualifications than controls ([Table 1](#)). Cases were more likely to report regular travel to or a long-term stay (≥ 3 months) in a high-TB region. A higher proportion of cases than controls reported drinking at a hazardous or harmful level and reported being a smoker. The proportion of cases reporting having used class A drugs was twice as high as in controls. Similarly, a history of having ever been in prison or homelessness was more frequent in cases than controls.

We were unable to trace NHS vaccination records for 96% of participants. For those traced with BCG vaccination recorded, 94% (34/36) either recalled BCG vaccination or had a BCG scar. For those traced and no BCG recorded, 71% had a BCG scar. Records were therefore not used. As there was a good level of agreement between self-reported history and scar inspection (86% agreement, kappa = 0.6, $p < 0.001$),¹⁷ information on self-reported history and scar examination were combined to classify the BCG status of participants (as shown in [Table 2](#)). Controls were more likely to have had BCG vaccination than cases.

Estimated effects of BCG vaccine on TB according to time since vaccination, for each model, are shown in [Table 3](#). Area-level deprivation and education level met our retention criterion and were included in the partially adjusted model. In the fully adjusted model, we adjusted additionally for smoking, alcohol, use of controlled drugs, regular travel abroad to a high-TB region, history of homelessness and history of prison stays. The remaining variables (long-term travel abroad to a high-TB region, average number of people per room, average number of people per bedroom) did not meet our retention criterion.

In the complete case analyses, fewer than 1% of individuals were excluded because information was missing on BCG vaccination but a larger proportion were excluded because of missing information on confounding variables (17% in the fully adjusted model). The baseline model shows evidence of a moderate protective effect of BCG up to 25 years post vaccination ([Table 3](#)). This was attenuated in the partially adjusted model: the protective effect 20–25 years post vaccination was low. Results were similar, though with narrower confidence intervals (CIs), when the baseline and partially adjusted models included all subjects

Table 1. Characteristics of study participants by case and control status

Characteristic	Cases		Controls	
	(n = 677)	%	(n = 1170)	%
Birth cohort				
1965–69	65	9.6	174	14.9
1970–74	178	26.3	312	26.7
1975–79	215	31.8	260	22.2
1980–89	219	32.4	424	36.2
Sex				
Female	341	50.4	700	59.8
Male	336	49.6	470	40.2
Quintiles of LSOA-level index of multiple deprivation				
1 (least deprived)	63	9.3	234	20.0
2	99	14.6	234	20.0
3	109	16.1	234	20.0
4	130	19.2	234	20.0
5 (most deprived)	276	40.8	234	20.0
Highest educational (academic, professional and/or vocational) qualification				
None	132	19.5	75	6.4
O levels or equivalent ^a	207	30.6	363	31.0
A levels or equivalent ^b	91	13.4	246	21.0
Degree level or equivalent ^c	216	31.9	455	38.9
Missing	31	4.6	31	2.7
Average number of people per room				
Fewer than or equal to 1	634	93.7	1144	97.8
Greater than 1	26	3.8	24	2.1
Missing	17	2.5	2	0.2
Average number of people per bedroom				
Fewer than or equal to 1	385	56.9	705	60.3
Greater than 1	275	40.6	463	39.6
Missing	17	2.5	2	0.2
TB infection risk from regular travels abroad				
Low ^d	618	91.3	1099	93.9
High ^e	58	8.6	71	6.1
Missing	1	0.2	0	0.0
TB infection risk from long-term (≥3 months) stays abroad				
Low ^d	607	89.7	1113	95.1
High ^e	70	10.3	57	4.9
Alcohol drinking^f				
Very low/no risk	166	24.5	329	28.1
Low risk	346	51.1	632	54.0
Hazardous risk	36	5.3	68	5.8
Harmful risk	41	6.1	25	2.1
Missing	88	13.0	116	9.9
Tobacco smoking				
Never smoker	188	27.8	499	42.7
Ex-smoker	62	9.2	135	11.5
Smoker: <20 pack-years	308	45.5	422	36.1
Smoker: ≥20 pack-years	99	14.6	85	7.3
Missing	20	3.0	29	2.5
Drug misuse/abuse^g				
No drug use	379	56.0	847	72.4

(continued)

Table 1. Continued

Characteristic	Cases		Controls	
	(n = 677)	%	(n = 1170)	%
Class B and/or C use only	69	10.2	108	9.2
Class A use	217	32.1	188	16.1
Missing	12	1.8	27	2.3
History of homelessness				
Never been homeless for >1 week	553	81.7	1091	93.2
Ever been homeless for >1 week	117	17.3	68	5.8
Missing	7	1.0	11	0.9
History of prison stay^h				
Never detained	590	87.2	1119	95.6
Ever detained in the UK or abroad	82	12.1	35	3.0
Missing	5	0.7	16	1.4

^aO levels, GCEs or GCSEs (any grades), City & Guilds Craft/Ordinary Level or NVQ Level 1 or 2. ^bA levels, SCE Higher, ONC/OND/BEC/TEC, City & Guilds Advanced Final Level or NVQ Level 3. ^cDegree level, teaching qualification, HNC/HND, BEC/TEC Higher or BTEC Higher. ^dRegular travel (i.e. every few years or more often) or long-term (>3 months) stay to Eastern Europe, Caribbean or none of the places specified. ^eRegular travel (i.e. every few years or more often) or long-term (≥3 months) stays to Africa or Asia. ^fAlcohol drinking based on combination on drinking frequency and quantity in UK standard units, and cut-offs by gender as proposed by Rehm *et al.*³³ Cut-offs for hazardous and harmful drinking, respectively, (20 g/day and 40 g/day) in women and (40 g/day and 60 g/day) in men. Subjects who stopped drinking 5 years or more ago classified as low risk. ^gClass B and C examples included benzodiazepines, cannabis, qat, glue, gas, solvents and amphetamines. Class A drug examples included ecstasy, cocaine, crack, heroin, LSD and magic mushrooms. ^h72/82 (88%) cases and 33/35 (94%) controls with history of prison stay report only ever been in prison in the UK and not abroad.

with complete data for those models (see [Supplementary Table 2](#), available as [Supplementary Data](#) at *IJE* online). Based on the fully adjusted model, there was good evidence of a protective effect of BCG 10–15 years (HR 0.49, 95% CI 0.31, 0.79) and 15–20 years (HR 0.43, 95% CI 0.28, 0.67) since vaccination. The protective effect was lower after 20 years: and 20–25 years (HR 0.75, 95% CI 0.49, 1.14) and 25–29 years (HR 0.99, 95% CI 0.53, 1.84) since vaccination. These estimates correspond to a VE of 51%, 57%, 25% and 1%, 10–15, 15–20, 20–25 and 25–29 years since vaccination, respectively.

The results based on multiple imputation of the missing data also indicated lower protection more than 20 years after BCG vaccination ([Table 3](#)). Estimated VEs were 56%, 57%, 25% and 21%, 10–15, 15–20, 20–25 and 25–29 years since vaccination, respectively.

The association between BCG vaccination and log hazard of TB modelled using restricted cubic splines with three knots at 15, 20 and 25 years post vaccination did not fit

Table 2. BCG vaccination status based on a combination of self-report and scar reading, among 677 cases and 1170 controls

Self-reported history	Scar inspection	Cases (<i>n</i> = 677)	Controls (<i>n</i> = 1170)	Assigned vaccination status	Cases	Controls
Convincing ^a BCG	Present	391 (57.8%)	776 (66.3%)	'Vaccinated'	473 (69.9%)	933 (79.7%)
Convincing BCG	None	57 (8.4%)	117 (10%)			
Convincing BCG	NI	22 (3.2%)	29 (2.5%)	'Likely vaccinated' ^b	33 (4.9%)	78 (6.7%)
Probable ^a BCG	Present	3 (0.4%)	11 (0.9%)			
Probable BCG history	None	3 (0.4%)	18 (1.5%)			
Probable BCG history	NI	0 (0%)	3 (0.3%)	'Not vaccinated'	163 (24.1%)	154 (13.2%)
No BCG history	Present	16 (2.4%)	27 (2.3%)			
Unsure	Present	14 (2.1%)	30 (2.6%)	Missing	8 (1.2%)	5 (0.4%)
No BCG history	None	135 (19.9%)	122 (13.4%)			
No BCG history	NI	19 (2.8%)	20 (1.7%)			
Unsure	None	9 (1.3%)	12 (1.0%)			
Unsure	NI	8 (1.2%)	5 (0.4%)			

NI, not inspected. ^aIf there was recall of being given BCG at school and either a clear recall of a prior tuberculin skin test (TST) or a pustule or scarring post vaccination, this was categorized as a convincing history; if only recall of BCG at school, it was categorized as probable. ^bSensitivity analysis moving this category to the vaccinated did not change the effect estimate of the association between BCG and TB and had small numbers; they were therefore assigned to the vaccinated category in the rest of the results.

Table 3. Results from complete case analyses (based on the 532 cases and 993 controls used in the fully adjusted model) and from analyses of 677 cases and 1170 controls based on multiple imputation

	Baseline model ^a		Partially adjusted model ^b		Fully adjusted model ^c	
	HR (95% CI)	<i>p</i>	HR (95% CI)	<i>p</i>	HR (95% CI)	<i>p</i>
Complete case analyses						
Unvaccinated	1 (ref.)		1 (ref.)		1 (ref.)	
Vaccinated 10–15 years ago	0.43 (0.28, 0.66)	<0.001	0.49 (0.31, 0.79)	0.004	0.49 (0.31, 0.79)	0.003
Vaccinated 15–20 years ago	0.34 (0.23, 0.50)	<0.001	0.41 (0.27, 0.63)	<0.001	0.43 (0.28, 0.67)	<0.001
Vaccinated 20–25 years ago	0.56 (0.39, 0.80)	0.001	0.69 (0.46, 1.02)	0.065	0.75 (0.49, 1.14)	0.174
Vaccinated 25–29 years ago	0.70 (0.40, 1.24)	0.225	0.88 (0.48, 1.59)	0.660	0.99 (0.53, 1.84)	0.970
Analyses based on multiple imputation						
Unvaccinated			1 (ref.)		1 (ref.)	
Vaccinated 10–15 years ago			0.43 (0.29, 0.67)	<0.001	0.44 (0.28, 0.67)	<0.001
Vaccinated 15–20 years ago			0.42 (0.29, 0.62)	<0.001	0.43 (0.29, 0.64)	<0.001
Vaccinated 20–25 years ago			0.70 (0.49, 1.00)	0.049	0.75 (0.52, 1.10)	0.141
Vaccinated 25–29 years ago			0.71 (0.42, 1.19)	0.195	0.79 (0.45, 1.39)	0.406

^aThe baseline model is stratified on birth cohort and adjusted for sex. ^bThe partially adjusted model is additionally adjusted for confounding variables area-level deprivation and educational level. ^cThe fully adjusted model has additional adjustment for lifestyle confounding variables (tobacco smoking, alcohol drinking and misuse/abuse of controlled drugs), history of homelessness, history of prison stays, TB infection risk from regular travels abroad.

the data better than the linear model (based on the AIC). Results from analyses based on the simpler linear model suggested an estimated 7% (95% CI: 0.2–12%) increase in the log of the HR with each year from 10 years post vaccination (Figure 1). The results using multiple imputation were similar to those from the complete case analysis, suggesting some protective effect of the vaccine up to about 25 years post vaccination. The spline model suggested a fairly constant level of vaccine effectiveness up to around 17 years post vaccination, and then a steeper reduction in the VE after that (see Supplementary Figure 2, available as Supplementary Data at *IJE* online).

Discussion

Based on a large, population-based case–control study, there was about a 50% protection against TB between 10 and 20 years following school-aged BCG vaccination, with little evidence of good protection after 20 years. Although numbers were small, there appeared to be subsequent waning in protection. Results from complete case analyses and multiple imputation to deal with missing data were consistent.

We had a moderately good response rate from cases and controls recruited to represent the children born in the UK in the general population. As we were able to locate




Figure 1. Results from modelling the time-varying effect of the vaccine as a linear function of time (on a log scale). The left-hand vertical axis shows the vaccine effectiveness (VE) and the right-hand vertical axis shows the hazard ratio (HR), both on the log scale. Results are based on the fully adjusted model. The dashed lines show the 95% confidence bounds.

few vaccination records, we relied upon self-report of BCG vaccination and inspection of participants for BCG scars to ascertain BCG vaccination status. The correspondence between the histories and the scar inspections was good. There was some confounding in estimating the protective effect of BCG, due to lower BCG uptake in poorer subjects who had a higher risk of TB, but we were able to control for this in the analysis.

A limitation in our approach was the inability to assess and exclude subjects who had a positive TST in the school vaccination programme, who would have been ineligible for vaccination. Retrospective ascertainment of results of TST testing based on recall was not feasible, and participants' recall could not be validated in the absence of records. Persons who have a positive response to a TST are known to be at higher risk of TB during the first few years after testing. However, follow-up data from the British MRC BCG trial in adolescents showed that, in that low-transmission setting, the risk of TB in participants with a positive TST test declined over time, and was similar to that of subjects who were TST-negative at baseline by about 10 years after enrolment^{24,25} (see Figure 11 in ref. 17 for details). Thus, not taking account of the TST results is unlikely to bias the association between BCG vaccination and TB beyond 10 years after vaccination. Also, extrapolation from modelling work²⁶ suggests that, in our study, the prevalence of tuberculin positivity in the White population would have been no greater than 4% at the time and age of screening for vaccination.

Other limitations include the possibility that subjects taking part are more likely to have been vaccinated than

those not contactable or who had refused. Cases were somewhat harder to contact than controls. Together with a higher response rate in cases than in controls, this might, if anything, have acted to underestimate the protective effect of BCG. After 20 years, a protective effect could no longer be detected after adjustment for confounding in the baseline model. Control for a wide range of confounders made little difference to the HR 10–20 years after vaccination, suggesting that, if there were any other unmeasured confounders or residual confounding, they may have limited effect.

This study provides evidence that adds to that from the original UK MRC trial, in which protection of 63% was reported 10–15 years after vaccination (with wide 95% CI, 17–84%). In that trial, there was no evidence of protection 15–20 years after vaccination but the numbers of cases were small and the CI consequently very wide (VE 9%, 95% CI <0–71%).²⁴ The apparent waning of protection after 20 years has also been seen in Norway, where moderately good protection was noted for 10–19 years after childhood BCG (VE 58%, CI 27%, 76%) and lower protection 20–29 years after vaccination (VE 38%, CI –32 to 71%).¹⁴ In a Brazilian cohort, protection in 15- to 20-year-olds after infant BCG vaccination was 39% (9–58%), but with no data in older individuals.²⁷ Other evidence for the duration of protection in high-prevalence settings is limited. A protective effect was noted in a case-control study in Saudi Arabian 15- to 24-year-olds after infant BCG vaccination (VE 67%, 95% CI 55–77%), but not in 25- to 34-year-olds (VE 20%, CI –6 to 37%).²⁸ In contrast, in an extended follow-up of a BCG trial in US Native-Americans, protection up to 60 years was reported.¹³ However, it is unclear whether such a long follow-up might have acted to select those at lower risk of TB. The above studies also do not indicate whether the protective effect of BCG in childhood is more durable, when it is assumed immune responses are better, than in infancy.

It has been suggested that, in high-transmission settings and areas closer to the equator, masking of the effect of BCG occurs by infection or sensitization by environmental mycobacteria increasingly providing, over time, some protection in the unvaccinated.^{5,6,29,30} The studies so far on durability of BCG have limited information with which to assess the role of masking.

In summary, our case-control study suggests BCG vaccination in UK-born adolescents provided protection against tuberculosis for at least 20 years. BCG at school age may have helped in the control of TB, including reducing the risk of multidrug-resistant disease, as those vaccinated around 13 years of age have been protected into adulthood. WHO's End TB strategy notes the importance

of continuing infant BCG vaccination in high-prevalence settings.^{31,32} We suggest also including a recommendation for childhood vaccination when infant vaccination has not been given. Our finding of longer duration of BCG protection may be helpful for countries assessing the cost-effectiveness of BCG in the prevention of tuberculosis. It also has implications for assessing new vaccines against tuberculosis, which should desirably provide protection that is greater than that from BCG and which might also be expected to provide lasting protection, although assessment of the latter would, in the short term, have to be based on immunological characteristics.

Supplementary Data

Supplementary Data are available at *IJE* online.

Funding

This work was supported by the National Institutes of Health Research Health technology Assessment (NIHR HTA) grant no 08/17/01. Other funding included a National Institute for Health Research (NIHR) Senior Investigator award NF-SI-0611-10168 (J.S.) NIHR Senior Investigator award NF-SI-0616-10037 (I.A.) and support from the MRC (I.A., L.R., P.M.), NIHR (I.A., L.R.), BBSRC (P.M.) and PHE (I.A.).

Acknowledgements

We thank the research team, interviewers, supervisors and the operation team members at NatCen as well as all the individuals who took part in the study. We also thank Lucy Trinder for help in data cleaning and management, colleagues from the TB Section, PHE, Child Health Information Services data managers, immunization coordinators and our steering group team for support and advice. L.R. and P.M. conceived the study. P.M. and P.N.D. supervised the fieldwork and data management. P.M., P.N.D. and L.R. provided academic leadership and other authors provided academic expertise and advice at key points. P.N.D. and R.K. carried out data cleaning and merging of data across sources. R.K. devised and carried out the analyses with assistance from P.N.D. Additional expertise was provided in statistics and presentation of the results (J.S.); BCG epidemiology and study design (P.F., P.S.); TB epidemiology in England, BCG vaccine records and public health (I.A., J.W., D.E. and M.L.) and estimating PPD positivity levels in the general population (E.V.). P.M. and P.N.D. wrote a first draft with R.K. All authors contributed to this paper.

Conflict of interest: The authors have no conflicts of interest to declare.

References

- World Health Organization. *Global Tuberculosis Report 2016*, 30 December 2016. <http://apps.who.int/iris/bitstream/10665/250441/1/9789241565394-eng.pdf?ua=1> (4 July 2017, date last accessed).
- Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. *Am J Epidemiol* 1974;**99**:131–8.
- Public Health England. *Tuberculosis in England 2016* (presenting data to end of 2015), 2016. <https://www.gov.uk/government/publications/tuberculosis-in-england-annual-report> (13 July 2017, date last accessed).
- Kaufmann SH, Lange C, Rao M *et al.* Progress in tuberculosis vaccine development and host-directed therapies—a state of the art review. *The Lancet Respiratory Medicine* 2014;**2**:301–20.
- Fine PEM. Variation in protection by BCG: Implications of and for heterologous immunity. *Lancet* 1995;**346**:1339–45.
- Mangtani P, Abubakar I, Ariti C *et al.* Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. *Clin Infect Dis* 2014;**58**:470–80.
- Roy A, Eisenhut M, Harris RJ *et al.* Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. *BMJ* 2014;**349**:g4643.
- Hart PD, Sutherland I. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life: final report to the Medical Research Council 5535. *Brit Med J* 1977;**2**:293–5.
- Sutherland I. Effectiveness of BCG vaccination in England and Wales in 1983. *Tubercle* 1987;**68**:81–92.
- Sterne JA, Rodrigues LC, Guedes IN. Does the efficacy of BCG decline with time since vaccination? *Int J Tuberc Lung Dis* 1998;**2**:200–7.
- Abubakar I, Pimpin L, Ariti C *et al.* Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guerin vaccination against tuberculosis. *Health Technol Assess* 2013;**17**:1–372.
- Barreto ML, Cunha SS, Pereira SM *et al.* Neonatal BCG protection against tuberculosis lasts for 20 years in Brazil 1251. *Int J Tuberc Lung D* 2005;**9**:1171–3.
- Aronson NE, Santosham M, Comstock GW *et al.* Long-term efficacy of BCG vaccine in American Indians and Alaska natives: a 60-year follow-up study. *JAMA—J Am Med Assoc* 2004;**291**:2086–91.
- Nguipod-Djomo P, Heldal E, Rodrigues LC *et al.* Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study. *Lancet Infect Dis* 2016;**16**:219–26.
- Gorak-Stolinska P, Weir RE, Floyd S *et al.* Immunogenicity of Danish-SSI 1331 BCG vaccine in the UK: comparison with Glaxo-Evans 1077 BCG vaccine. *Vaccine* 2006;**24**:5726–33.
- Office TNA. *Procurement of Vaccines by the Department of Health 2003*, 12 October 2016. <https://www.nao.org.uk/wp-content/uploads/2003/04/0203625.pdf> (4 July 2017, date last accessed).
- Mangtani P, Nguipod-Djomo P, Keogh R, Trinder L *et al.* NIHR/HTA study 08/17/01: observational study to estimate the changes in the effectiveness of BCG with the time since vaccination for preventing tuberculosis in the UK. *Health Technol Assess* 2017;**21**(39). <https://www.journalslibrary.nihr.ac.uk/hta/hta21390/#/abstract>.
- Office for National Statistics. *The English Indices of Deprivation 2010*, 2011. <https://www.gov.uk/government/statistics/english-indices-of-deprivation-2010> (4 July 2017, date last accessed).
- Keogh RH, Cox DR. *Case-Subcohort Studies: Case-Control Studies*. Cambridge: Cambridge University Press, 2014, 191–211.
- Prentice RL. A case-cohort design for epidemiologic cohort studies and disease prevention trials. *Biometrika* 1986;**73**:1–11.

21. Keogh RH, Mangtani P, Rodrigues L *et al.* Estimating time-varying exposure-outcome associations using case-control data: logistic and case-cohort analyses. *BMC Med Res Methodol* 2016;**16**:2.
22. Aikake H. Information Theory and an Extension of the Maximum Likelihood Principle. In: Petrov B N and Csaki F (eds), Second International Symposium on Information Theory, Budapest, Hungary: Akademiai Kiado, 1973, pp.267-81.
23. Sterne JA, White IR, Carlin JB *et al.* Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. *BMJ* 2009;**338**:b2393.
24. Hart PD, Sutherland I. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life: final report to the Medical Research Council. *Brit Med J* 1977;**2**:293-5.
25. Fourth report to the Medical Research Council by its Tuberculosis Vaccines Clinical Trials Committee: BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. *B World Health Organ* 1972;**46**:3-85.
26. Vynnycky E, Fine PE. The annual risk of infection with *Mycobacterium tuberculosis* in England and Wales since 1901. *Int J Tuberc Lung Dis* 1997;**1**:389-96.
27. Barreto ML, Cunha SS, Pereira SM *et al.* Neonatal BCG protection against tuberculosis lasts for 20 years in Brazil. *Int J Tuberc Lung Dis* 2005;**9**:1171-3.
28. Al Kassimi FA, Al Hajjaj MS, Al Orainey IO *et al.* Does the protective effect of neonatal BCG correlate with vaccine-induced tuberculin reaction? *Am J Resp Crit Care Med* 1995;**152**:1575-8.
29. Palmer CE, Long MW. Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis. *Am Rev Respir Dis* 1966;**94**:553-68.
30. Valadas E. Nontuberculous mycobacteria: clinical importance and relevance to bacille Calmette-Guerin vaccination. *Clin Infect Dis* 2004;**39**:457-8.
31. Uplekar M, Weil D, Lonnroth K *et al.* WHO's new end TB strategy. *Lancet* 2015;**385**:1799-1801.
32. Organization WH. *Documentation for World Health Assembly 67*. Geneva: WHO, 2014. http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_11-en.pdf (4 July 2017, date last accessed).
33. Rehm J, Greenfield TK, Walsh G *et al.* Assessment methods for alcohol consumption, prevalence of high risk drinking and harm: a sensitivity analysis. *Int J Epidemiol* 1999;**28**:219-24.